Conferences AASLD2017
Other Infections
AASLD 2017: Treatment that Interferes with Viral Assembly Shows Promise for Hepatitis B
- Details
- Category: Experimental HBV Drugs
- Published on Sunday, 17 December 2017 00:00
- Written by Liz Highleyman
JNJ-56136379, an experimental drug that interferes with assembly of the hepatitis B virus (HBV) capsid, demonstrated potent antiviral activity in an early clinical trial, researchers reported at the recent 2017 AASLD Liver Meeting in Washington, DC.
AASLD 2017: RNA Interference Therapy Lowers Viral Biomarker in People with Hepatitis B
- Details
- Category: Experimental HBV Drugs
- Published on Friday, 15 December 2017 00:00
- Written by Liz Highleyman
ARB-1467, a novel type of treatment for hepatitis B, reduced levels of hepatitis B surface antigen (HBsAg) when used alone, and it may play a role in combination therapy to cure the infection, researchers reported at the recent 2017 AASLD Liver Meeting in Washington, DC.
AASLD 2017: TAF for Hepatitis B Improves Kidney Function and Bone Loss
- Details
- Category: HBV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by Liz Highleyman
Tenofovir alafenamide (TAF) remains effective against hepatitis B virus (HBV) for 96 weeks, with no resistance detected, according to studies presented at the 2017 AASLD Liver Meeting last month in Washington, DC.
AASLD 2017: Immune Modulator Inarigivir Looks Promising for Hepatitis B
- Details
- Category: Experimental HBV Drugs
- Published on Wednesday, 13 December 2017 00:00
- Written by Liz Highleyman
Inarigivir, or SB 9200, an immune-modulating drug that has a dual mechanism of action against hepatitis B virus (HBV), reduced levels of HBV DNA, RNA, and antigens, and potency was enhanced when followed by tenofovir, according to early results from the ACHIEVE trial presented at the recent 2017 AASLD Liver Meeting in Washington, DC.
AASLD 2017: More Work and Lower Drug Prices Needed to Eliminate Hepatitis C Worldwide
- Details
- Category: HCV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by Liz Highleyman
Eliminating hepatitis C virus (HCV) as a global public health concern is feasible, but to do so more people need to be tested and treated, and prices of direct-acting antivirals need to come down, according to presentations at the AASLD Liver Meeting last month in Washington, DC.
AASLD 2017: Women with Fatty Liver Disease at Higher Risk for Heart Disease
- Details
- Category: Steatosis/NAFLD/NASH
- Published on Wednesday, 13 December 2017 00:00
- Written by Liz Highleyman
Women with non-alcoholic fatty liver disease (NAFLD) had a higher risk of cardiovascular events including chest pain and heart failure compared to women without the condition -- and about the same risk as men with NAFLD -- in a study presented at the 2017 AASLD Liver Meeting in October in Washington, DC.
AASLD 2017: TAF for Hepatitis B Improves Kidney Function and Bone Loss
- Details
- Category: HBV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by Liz Highleyman
Tenofovir alafenamide (TAF) remains effective against hepatitis B virus (HBV) for 96 weeks, with no resistance detected, according to studies presented at the 2017 AASLD Liver Meeting last month in Washington, DC.
AASLD 2017: Nivolumab Improves Outcomes in Liver Cancer Study
- Details
- Category: Liver Cancer/HCC
- Published on Thursday, 30 November 2017 00:00
- Written by Liz Highleyman
Nivolumab (Opdivo), a PD-1 checkpoint inhibitor that helps the immune system fight cancer, was associated with a decrease in tumor size or disease stabilization in patients with hepatocellular carcinoma (HCC) in the CheckMate 040 study, according to a report at the 2017 AASLD Liver Meeting last month in Washington, DC.
AASLD 2017: Sofosbuvir/Ledipasvir for 8 Weeks Cures Acute HCV in People with HIV
- Details
- Category: HCV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by Liz Highleyman
An 8-week course of sofosbuvir/ledipasvir (Harvoni) led to sustained response in all HIV-positive with genotype 1 or 4 acute hepatitis C virus (HCV) infection in the SWIFT-C study, according to a reportat the AASLD Liver Meeting last month in Washington, DC.
More Articles...
- AASLD 2017: Sofosbuvir/Ledipasvir for 8 Weeks Cures Acute HCV in People with HIV
- AASLD 2017: REP 2139 Combination Therapy Leads to Functional Control of Hepatitis B Virus
- U.S. Approves New Hepatitis B Vaccine as Public Health Agencies Update Guidelines
- Coverage of the 2017 AASLD Liver Meeting
- Coverage of the 2017 AASLD Liver Meeting
- AASLD 2017: Model Shows Hepatitis C Treatment is Cost-Effective in Japan
- AASLD 2017: Hepatitis C Testing Linked to Reduced Opioid Use
- AASLD 2017: Daily Aspirin Linked to Lower Liver Cancer Risk for Hepatitis B Patients
- AASLD 2017: Experimental NASH Therapy Improves Liver Fat and Fibrosis
- AASLD 2017: Curing Hepatitis C Leads to Improved Quality of Life
- AASLD 2017: Mavyret Shows High Cure Rates for HCV Genotype 3 and Cirrhosis
- AASLD 2017: Curing Hepatitis C with DAAs Reduces Liver Cancer Risk
- AASLD 2017: HCV Infections Are Rising Among HIV+ Gay Men In San Diego
Web Design and Development by